BridgeBio Will Present Phase 3 Encaleret Data in October
The company will share trial results on bone health and patient outcomes in genetic conditions this October.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Should companies prioritize the development of new treatments for rare genetic conditions?
BridgeBio Pharma is scheduled to present Phase 3 data for its investigational drug encaleret at the ASBMR 2026 Annual Meeting in Boston. The presentations, occurring October 9-12, 2026, will feature findings from the 24-week CALIBRATE trial.
Why it matters
The data release will provide insight into the efficacy of this orally administered small molecule for treating Autosomal dominant hypocalcemia type 1. These results aim to clarify the drug's impact on patient-reported outcomes and bone turnover markers.
The upcoming presentations cover a 24-week period from the CALIBRATE trial of encaleret, an investigational small molecule. Researchers will detail how the drug influences bone turnover and symptom burden in patients.
The players
BridgeBio Pharma
A biotechnology company based in Palo Alto that focuses on developing small molecule and genetic medicines for rare conditions.
HypoPARAthyroidism Association
An advocacy organization that has collaborated with BridgeBio on regional family cascade genetic testing events.
The details
Encaleret is designed as an orally administered small molecule to treat Autosomal dominant hypocalcemia type 1, a condition caused by gain-of-function variants in the CASR gene. These genetic variants cause the calcium-sensing receptor to become hyperactive, leading to low blood calcium levels. The trial evaluates the molecule's ability to modulate this pathway and normalize calcium handling compared to current standards.
Timeline
October 9-12, 2026: ASBMR 2026 Annual Meeting in Boston.
October 10, 2026: Poster presentations on symptom burden and genetic testing.
October 11, 2026: Oral presentations on encaleret and achondroplasia.
The Tech Race
The data presentation marks a milestone for an active research program that seeks to address the underlying genetic drivers of Autosomal dominant hypocalcemia type 1. This trial follows previous attempts to manage the condition through symptomatic treatment rather than molecular modulation.
The clinical trial results will provide families affected by Autosomal dominant hypocalcemia type 1 a clearer picture of the investigational drug's efficacy profile. Encaleret currently holds U.S. FDA Fast Track Designation, which is intended to facilitate the development and review of drugs for serious conditions.
The takeaway
Investors and clinicians should watch the October 11, 2026, oral presentations for the specific patient-reported outcomes from the 24-week CALIBRATE trial. These results will determine the next steps in the regulatory path for encaleret.
Further reading
For more on clinical developments in genetic medicine, visit the Biotech section.
Live Poll
Should companies prioritize the development of new treatments for rare genetic conditions?
